Billing Code Overview

HCPCS Level II code C9485 describes Injection, olaratumab, 10 mg. The service reflects administration of the oncology biologic olaratumab in a single billed unit representing 10 mg of the drug.

Service type: Drug administration / Injectable oncology therapy

Typical site of service: Outpatient hospital infusion center or clinic (ambulatory infusion setting)

Data not available in the input.

Clinical Context

A typical patient is an adult with advanced or metastatic soft tissue sarcoma receiving systemic targeted therapy. The patient presents to an outpatient oncology infusion center for administration of C9485 (injection, olaratumab, 10 mg). Prior to infusion, the oncology nurse verifies identity, obtains vital signs, reviews chemotherapy orders and recent labs (including CBC, CMP), and confirms premedication orders. The provider documents diagnosis, planned dose based on body surface area or weight per protocol, and obtains informed consent. Olaratumab is prepared by pharmacy under sterile conditions and delivered to the infusion suite. The infusion nurse administers supportive medications as ordered (e.g., antiemetic, antihistamine, corticosteroid if indicated), initiates the infusion through peripheral IV or central venous access, monitors for infusion-related reactions, records infusion start/stop times, documents lot number and expiration for the biologic, and provides discharge instructions. Follow-up includes assessment of response by imaging and oncology clinic visits to evaluate toxicity and ongoing dosing intervals.

Coding Specifications

59 | Distinct procedural service | Use when two services on the same day are unrelated and independent from the olaratumab administration.

76 | Repeat procedure or service by same physician | Use if the same service (e.g., infusion administration) is repeated later the same day by the same provider.

77 | Repeat procedure by another physician | Use if a different physician repeats the same service later the same day.

91 | Repeat clinical diagnostic laboratory test | Use when repeat lab testing is performed during the same encounter to confirm patient status prior to infusion.

G0 | Services related to COVID-19 vaccine counseling/testing (Medicare) | Use only when applicable per payer rules for COVID-related encounters co-occurring with infusion services (rare for this code).

XE | Separate encounter, a distinct service | Use under NCCI-associated modifier rules when service is separate and distinct and other modifier requirements are met.

XP | Separate practitioner | Use when different practitioners perform substantially separate portions of care related to the infusion.

XU | Unusual non-overlapping service | Use when services are distinct and do not overlap in time or resources with the olaratumab administration.

RT | Right side | Use when laterality is required for procedures or supplies associated with the infusion access (rare for IV biologics).

363L00000X | Oncology Nursing | Infusion nurses who administer biologic therapies in outpatient settings.

207RH0000X | Radiation Oncology | Occasionally involved in multidisciplinary sarcoma care; may coordinate with systemic therapy.

208800000X | Internal Medicine | Hospitalists or internists who may manage inpatient administration or comorbid conditions.

3336C0001X | Pharmacy | Oncology pharmacists who prepare and verify sterile biologic infusions.

Related Diagnoses

C49.9 | Malignant neoplasm of connective and soft tissue, unspecified | Represents sarcoma diagnoses where olaratumab may be considered as systemic therapy.

C79.31 | Secondary malignant neoplasm of brain and cerebral meninges | Metastatic spread sites that may be present in advanced sarcoma patients receiving systemic biologics.

C79.89 | Secondary malignant neoplasm of other specified sites | Used for metastases to less common sites when treating advanced disease with systemic agents.

Z51.11 | Encounter for antineoplastic chemotherapy | Used to indicate the encounter is for administration of systemic antineoplastic therapy such as olaratumab.

Z92.21 | Personal history of antineoplastic chemotherapy | Documented when patient has prior chemotherapy exposure relevant to current treatment planning.

C80.1 | Malignant neoplasm, primary site unknown | Sometimes used when cancer histology or primary site is uncertain and systemic therapy is being administered.

D63.0 | Anemia in neoplastic disease | Common comorbidity in oncology patients that may affect treatment tolerance and monitoring during infusion.

Related CPT Codes

96415 | Chemotherapy administration, IV infusion, each additional hour (List separately in addition to code for primary infusion) | Billed for additional infusion time beyond the initial hour when infusion duration for C9485 administration requires extended time.

96417 | Chemotherapy administration, IV push, each additional substance/drug (different from initial) | Billed when multiple IV therapeutic drugs are administered sequentially during the same visit in addition to the primary infusion.

96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | May be used for non-chemotherapy biologic infusions depending on payer rules and clinical context for olaratumab administration.

36415 | Collection of venous blood by venipuncture | Performed prior to infusion for requisite lab monitoring (CBC, CMP) and billed as appropriate.

99070 | Supplies and materials (e.g., IV tubing, saline), provided by the physician over and above those usually included with the service | May be used to report additional non-covered infusion supplies associated with the administration of C9485.